Eli Lilly Crushes Views As Zepbound, Mourjaro Sales Boom Investor’s Business DailyEli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar CNBCEli Lilly raises forecast after boost in Zepbound, Mounjaro sales Fox BusinessEli Lilly Stock Surges as Mounjaro and Zepbound Drugs Fuel Sales The Wall Street JournalLilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion Investors | Eli Lilly and Company